Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.42 |
| ▸ | RAB9A | P51151 | 7/20 | 0.42 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL312919 | 1.00 | MAPT (0.49) | MAPTALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL1355451 | 0.86 | ADRA2A (0.46) | MAPTALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL1355450 | 0.86 | ADRA2A (0.46) | MAPTALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL12998317 | 0.86 | ADRA2A (0.46) | MAPTALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL312502 | 0.80 | ALDH1A1 (0.49) | MAPTALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL312501 | 0.80 | ALDH1A1 (0.49) | MAPTALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL312357 | 0.76 | MAPT (0.51) | MAPTALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL312358 | 0.76 | MAPT (0.51) | MAPTALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL1356191 | 0.74 | ADRA2A (0.47) | MAPTALDH1A1KDM4EGAASMN1; SMN2 | |
| SCHEMBL1356192 | 0.74 | ADRA2A (0.47) | MAPTALDH1A1KDM4EGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349844-B2 | Substituted pyrazolo [1,5-A] pyrimidines as metabotropic glutamate antagonists | HOFFMANN-LA ROCHE INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GATTI MCARTHUR SILVIA (CH) | 2012-02-16 | — | — | US | disclosed |
| US-8093263-B2 | Substituted pyrazolo [1,5-a] pyrimidines as metabotropic glutamate antagonists | HOFFMANN-LA ROCHE INC. (US) | 2012-01-10 | — | — | US | disclosed |
| EP-1934214-B1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-04-07 | — | — | EP | disclosed |
| US-20090143580-A1 | SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | MCARTHUR SILVIA GATTI | 2009-06-04 | — | — | US | disclosed |
| US-7504404-B2 | Compounds as metabotropic glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1934214-A1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007039439-A1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143580-A1 | SUBSTITUTED PYRAZOLO [1,5-a] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GRM1, GRM2, GRM3 | MAPT 1112/4885ALDH1A1 1343/4885KDM4E 1714/4885 |
| US-20120041002-A1 | SUBSTITUTED PYRAZOLO [1,5-A] PYRIMIDINES AS METABOTROPIC GLUTAMATE ANTAGONISTS | GRM1, GRM2, GRM3 | MAPT 1112/4885ALDH1A1 1343/4885KDM4E 1714/4885 |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | GRM1, GRM2, GRM3 | MAPT 1442/4885ALDH1A1 1699/4885KDM4E 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.